Under the deal, Cooper Cos. will gain control over Teva’s manufacturing plant in Buffalo, N.Y., that solely makes Paragard.
The deal is expected to be completed by the end of 2017.
Teva, which is $35 billion in debt, will also divest its remaining global women’s health assets, and oncology and pain relief businesses in Europe to shore up finances, according to Reuters.
More articles on supply chain:
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals
Physicians rarely disclose payments from pharma when promoting drugs on Twitter
US government issues security warnings for hospital syringe pumps susceptible to hacking
